Announcements
Projects
Orgs
Project
Articles 49
Votes 0
Cancernetwork.com

Authors 62

Ariana Pelosci
Ian D. Davis
MBBS
PhD
Phillip H. Kuo
MD
E. David Crawford
Angela DeMichele
MSCE
Neeraj Agarwal
Simon Chowdhury
Bobby Liaw
Benjamin Lowentritt
David O'Malley
Nicholas Wrigley
Ibrahim Halil Sahin
Yancey Warren
Jr
MAT
Anna Hecksher
BS
Courtney Schepel
Sally Trufan
MS
Rebecca Greiner
PA
Susan Yaguda
MSN
RN
Chasse Bailey-Dorton
MSPH
Julie Fisher
Richard White
Lejla Hadzikadic-Gusic
MSc
Russ Conroy
Hayley Virgil
Miranda Lankas
Louis Potters
Minh-Tri Nguyen
Wei Wei
Gregory Cooper
Alok A. Khorana
Suneel D. Kamath
Richard L. Martin III
MPH
Stephen Schleicher
MBA
Ann H. Partridge
Fatma Betül Ayrak
Süheyla Aytaç Arslan
Yılmaz Tezcan
Rina Lokaj
Jennifer A. Vencill
LP
Neil M. Iyengar
William J. Catalona
Ritu Salani
Rakhshanda Rahman
FRCS
FACS
Amy Tiersten
Futibatinib Yields Clinical Benefit in FGFR2+ Intrahepatic Cholangiocarcinoma - Cancer Network
almost3y
Olaparib May Prolong PFS Regardless of Mutation Location in Ovarian Cancer - Cancer Network
almost3y
Radiation Oncology Remains 'Third Leg of the Stool' in Cancer Treatment, But Continues to Be Successful - Cancer Network
almost3y
Progressing From Disparity to Equity: Untangling the Complexities of Timely Care and the Rural Cancer Experience - Cancer Network
almost3y
Artificial Intelligence May Help Oncologists Better Risk-Stratify Patients With Prostate Cancer - Cancer Network
almost3y
Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors - Cancer Network
almost3y
Recent Data Validate Shorter Radiation Duration in Prostate Cancer - Cancer Network
almost3y
Chemotherapy Plus Endocrine Therapy Increases Cognitive Impairment in Breast Cancer - www.oncnursingnews.com/
almost3y
Teclistamab Combination Therapy Produces Promising Safety Profile in Relapsed/Refractory Multiple Myeloma - Cancer Network
almost3y
Talquetamab Continues to Show Robust Efficacy With Acceptable Safety in Heavily Pretreated Multiple Myeloma - OncLive
almost3y
Antonio Calles, MD, Highlights Promising Preliminary Activity of Lurbinectedin and Pembrolizumab in Relapsed SCLC - Cancer Network
almost3y
Integrative Oncology in Young Women With Breast Cancer - Cancer Network
almost3y
Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer - Cancer Network
almost3y
Opioid Use Disorder and Overdose Found to Be Rare but Significant After Stage II/III Colorectal Cancer Diagnosis - Cancer Network
~3y
Despite Presenting With More Aggressive Disease, Black Vs White Men With Prostate Cancer Have Improved Outcomes Following Radiotherapy - Cancer Network
~3y
David O'Malley, MD, Discusses PFS Benefit of Maintenance Rucaparib Regardless of Surgery Outcome in Newly Diagnosed Ovarian Cancer - Cancer Network
~3y
Metastatic CSPC: Future Directions in Care - Cancer Network
~3y
Multiprofessional Assessment and Information Day Associated With Shortened Hospital Stay Following Complex Oncologic Head and Neck Surgery - Cancer Network
~3y
Angela DeMichele, MD, MSCE, Analyzes Data Thus Far From I-SPY2 in HR+/HER2– Early Breast Cancer - Cancer Network
~3y
Phillip H. Kuo, MD, PhD, Evaluates Future Research Surrounding PSMA-PET Parameters and Response to 177Lu-PSMA-617 in mCRPC - Cancer Network
~3y
E. David Crawford, MD, Reviews Unmet Needs Addressed by FDA Approval of Darolutamide, Docetaxel, and ADT in mHSPC - Cancer Network
~3y
Phillip H. Kuo, MD, PhD, Examines Utility of PSMA-PET Parameters to Predict Response to 177Lu-PSMA-617 in mCRPC - Cancer Network
~3y
Ian D. Davis, MBBS, PhD, Reviews Interesting Data From TheraP Trial of 177Lu-PSMA-617 in mCRPC at 2022 ASCO - Cancer Network
~3y
Trevor M. Feinstein, MD, Examines Docetaxel With or Without Plinabulin in Stage IIIB/IV EGFR Wild-Type NSCLC - Cancer Network
~3y